NASDAQ · Biotechnology

PGEN (PGEN) Stock

$5.45 -1.45% NASDAQ: PGEN Healthcare

Valuation

MetricValue
Price$5.45
Market Cap$1.94B
P/E Ratio-2.99
P/B Ratio60.36
P/S Ratio38.70
EPS (TTM)$-1.41
52-Week High$6.03
52-Week Low$1.39
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1195.24%
ROA-159.87%
ROCE-509.52%
Gross Margin-1060.00%
Operating Margin-1070.00%
Net Margin-6.47%
Debt/Equity4.86
Current Ratio3.11

Annual Financials (USD)

Metric20212022202320242025
Revenue$14.0M$27.0M$6.0M$4.0M$10.0M
Operating Profit$-92.0M$-76.0M$-100.0M$-135.0M$-107.0M
Net Profit$-92.0M$28.0M$-96.0M$-126.0M$-251.0M
EPS$-0.47$-0.40$-0.39$-0.47$-1.41
Op Margin-644.5%-281.4%-1602.5%-3440.2%-1100.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$360.0M$216.0M$151.0M$145.0M$157.0M
Total Liabilities$253.0M$90.0M$33.0M$107.0M$136.0M
Cash$36.0M$5.0M$8.0M$30.0M$30.0M
Borrowings$190.0M$51.0M$7.0M$6.0M$5.0M

Latest News

What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors? Motley Fool · Jul 15, 2026 Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 Precigen Insider Sold Shares Worth $2,042,864, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason Insider Monkey · Jun 23, 2026 Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS Insider Monkey · Jun 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-56.0M$-65.0M$-67.0M$-68.0M$-88.0M
Investing Cash Flow$-82.0M$221.0M$-5.0M$-29.0M$-4.0M
Financing Cash Flow$1.0M$0$0$0$-3.0M
Net Cash Flow$-9.0M$5.0M$-41.0M$22.0M$1.0M
Free Cash Flow$-63.0M$-70.0M$-68.0M$-77.0M$-90.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-9.62%
Quick Ratio4.12
Interest Coverage-26.75
Return 1Y229.22%
Return 3Y333.73%
Return 5Y1.02%

Ownership

Insiders Held13.71%
Institutions Held71.19%
Institutions Float Held82.50%
Institutional HolderSharesReport Date
Patient Capital Management, LLC17,817,3872026-03-31
Blackrock Inc.15,223,1912026-03-31
State Street Corporation10,890,1242026-03-31
Vanguard Capital Management LLC7,148,9962026-03-31
Diametric Capital, Lp6,801,7882026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMLX $22.82 -5.66% -8.69 $2.54B 0.00%
DNTH $104.09 +2.44% -17.99 $4.35B 0.00%
ELVN $60.46 +0.32% -19.91 $4.32B 0.00%
IMTX $8.24 -4.52% -4.98 $1.10B 0.00%
NKTR $70.68 -0.13% -6.95 $1.38B 0.00%

About PGEN

PGEN is led by CEO Helen Sabzevari, employs 143 people, headquartered in US, publicly traded since 2013.

PGEN stock trades at $5.45 with a market capitalization of $1.94B. The stock is valued at a price-to-earnings (P/E) ratio of -2.99, price-to-book of 60.36, price-to-sales of 38.70. Over the past 52 weeks the stock has ranged between $1.39 and $6.03, and currently trades 9.6% below its 52-week high.

On profitability, PGEN generates a return on equity (ROE) of -1195.24%, return on capital employed of -509.52%, an operating margin of -1070.00%, a net profit margin of -6.47%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides